Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)

Aims To investigate real‐world short‐term clinical outcomes in adults with type 2 diabetes (T2D) who initiated semaglutide in a specialist endocrinology practice in Canada. Materials and methods This study was a retrospective observational study using data from the Canadian LMC Diabetes Registry. Adults with T2D who were naïve to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy, initiated semaglutide therapy as usual standard of care...